Ignite Creation Date:
2024-05-06 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 12:54 PM
Study NCT ID:
NCT03675347
Status:
UNKNOWN
Last Update Posted:
2018-09-18
First Post:
2018-09-07
Brief Title:
Recurrent Events After Percutaneous Coronary INterventio for ACS
Sponsor:
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Organization:
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Study Overview
Official Title:
Incidence Predictors and impAct on General Population of Recurrent Events After Percutaneous Coronary INterventio for ACS the AGAIN a Multicenter Study
Status:
UNKNOWN
Status Verified Date:
2018-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AGAIN
Brief Summary:
Patients undergoing PCI for ACS are exposed to a significant ischemic and bleeding risk
The aim of our study is instead to analyze in detail the rates of recurrent events but also their predictors and impact on outcomes in a population of unselected real life patients treated with PCI for ACS discharged on either Clopidogrel Prasugrel or Ticagrelor who already experienced an adverse event during the first year of follow up
The aim of our study is instead to analyze in detail the rates of recurrent events but also their predictors and impact on outcomes in a population of unselected real life patients treated with PCI for ACS discharged on either Clopidogrel Prasugrel or Ticagrelor who already experienced an adverse event during the first year of follow up
Detailed Description:
Patients undergoing PCI for ACS are exposed to a significant ischemic and bleeding risk The rate predictors and outcomes of an adverse event in this population has been already investigated However to the best of our knowledge only two papers took specifically in analysis rates of recurrence after a first event the first is a recently published article by Giustino et al it took in consideration recurrent events in a selected population of patients with ST-elevation Myocardial Infarction STEMI participating in the HORIZONS-AMI Trial discharged on Aspirin and Clopidogrel analyzing their incidence in the first year of follow-up The second is a paper by Fanaroff et al which primarily focused on the factors leading to a DAPT intensification in patients with recurrent events
The aim of our study is instead to analyze in detail the rates of recurrent events but also their predictors and impact on outcomes in a population of unselected real life patients treated with PCI for ACS discharged on either Clopidogrel Prasugrel or Ticagrelor who already experienced an adverse event during the first year of follow up
The aim of our study is instead to analyze in detail the rates of recurrent events but also their predictors and impact on outcomes in a population of unselected real life patients treated with PCI for ACS discharged on either Clopidogrel Prasugrel or Ticagrelor who already experienced an adverse event during the first year of follow up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None